Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Robert Walters downbeat on outlook as Q2 net fees drop

(Sharecast News) - Recruiter Robert Walters struck a downbeat tone on the outlook on Tuesday as it reported a drop in second-quarter fee income on Tuesday, citing macroeconomic uncertainty. Group net fee income fell 13% on the same period a year ago to £72.7m. The company said that while net fees were higher than in the first quarter, macroeconomic uncertainty became more pronounced, with forward indicators - new job flow and interviews - slightly weaker compared to the end of the first quarter.

Net fee income in Asia Pacific was down 9% to £32.9m, while Europe saw a 22% drop to £21.5m.

UK net fee income declined 8% to £12.1m, while Rest of World saw a 2% dip to £6.2m.

Chief executive Toby Fowlston said: "Geographically, we continued to see the most challenging conditions in Europe, with a more resilient performance in the UK and stable trends in Asia-Pacific.

"With the external environment continuing to constrain client and candidate confidence, our planning assumption remains that there will be no material improvement in hiring markets in the near term.

"However, we continue to have high conviction in our disciplined entrepreneurialism strategy and therefore took further strategic action during the quarter to drive greater efficiency. We exited the first half with our monthly cost base having reduced on 2024 levels, and anticipate further progress in the second half of the year."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.